Cargando…
The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid
Supplementation with n-3 polyunsaturated fatty acids (n-3 PUFAs) may be beneficial for patients with inflammatory bowel diseases (IBD). In this study we analyzed the pharmacokinetic profile of eicosapentaenoic acid (EPA), as the free fatty acid (FFA), in an enteric-coated preparation, in 10 ulcerati...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538368/ https://www.ncbi.nlm.nih.gov/pubmed/26339608 http://dx.doi.org/10.1155/2015/360825 |
_version_ | 1782385991897579520 |
---|---|
author | Scaioli, Eleonora Cardamone, Carla Liverani, Elisa Munarini, Alessandra Hull, Mark A. Belluzzi, Andrea |
author_facet | Scaioli, Eleonora Cardamone, Carla Liverani, Elisa Munarini, Alessandra Hull, Mark A. Belluzzi, Andrea |
author_sort | Scaioli, Eleonora |
collection | PubMed |
description | Supplementation with n-3 polyunsaturated fatty acids (n-3 PUFAs) may be beneficial for patients with inflammatory bowel diseases (IBD). In this study we analyzed the pharmacokinetic profile of eicosapentaenoic acid (EPA), as the free fatty acid (FFA), in an enteric-coated preparation, in 10 ulcerative colitis (UC) and 10 Crohn's disease (CD) patients and 15 healthy volunteers (HV). Subjects received 2 g daily of EPA-FFA for 8 weeks. Plasma phospholipid and red blood cell (RBC) membrane fatty acid content were measured by gas chromatography-mass spectrometry. There was a rapid incorporation of EPA into plasma phospholipids by 2 weeks and a slower, but highly consistent, incorporation into RBC membranes (4% total fatty acid content; coefficient of variation 10–16%). There was a concomitant reduction in relative n-6 PUFA content. Elongation and desaturation of EPA into docosahexaenoic acid (DHA) via docosapentaenoic acid (DPA) were apparent and DHA content also increased in membranes. EPA-FFA is well tolerated and no difference in the pharmacokinetic profile of n-3 PUFA incorporation was detected between IBD patients and HV. Our data support the concept that EPA can be considered the “universal donor” with respect to key n-3 PUFAs and that this enteric-coated formulation allows long term treatment with a high level of compliance. |
format | Online Article Text |
id | pubmed-4538368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-45383682015-09-03 The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid Scaioli, Eleonora Cardamone, Carla Liverani, Elisa Munarini, Alessandra Hull, Mark A. Belluzzi, Andrea Biomed Res Int Research Article Supplementation with n-3 polyunsaturated fatty acids (n-3 PUFAs) may be beneficial for patients with inflammatory bowel diseases (IBD). In this study we analyzed the pharmacokinetic profile of eicosapentaenoic acid (EPA), as the free fatty acid (FFA), in an enteric-coated preparation, in 10 ulcerative colitis (UC) and 10 Crohn's disease (CD) patients and 15 healthy volunteers (HV). Subjects received 2 g daily of EPA-FFA for 8 weeks. Plasma phospholipid and red blood cell (RBC) membrane fatty acid content were measured by gas chromatography-mass spectrometry. There was a rapid incorporation of EPA into plasma phospholipids by 2 weeks and a slower, but highly consistent, incorporation into RBC membranes (4% total fatty acid content; coefficient of variation 10–16%). There was a concomitant reduction in relative n-6 PUFA content. Elongation and desaturation of EPA into docosahexaenoic acid (DHA) via docosapentaenoic acid (DPA) were apparent and DHA content also increased in membranes. EPA-FFA is well tolerated and no difference in the pharmacokinetic profile of n-3 PUFA incorporation was detected between IBD patients and HV. Our data support the concept that EPA can be considered the “universal donor” with respect to key n-3 PUFAs and that this enteric-coated formulation allows long term treatment with a high level of compliance. Hindawi Publishing Corporation 2015 2015-08-03 /pmc/articles/PMC4538368/ /pubmed/26339608 http://dx.doi.org/10.1155/2015/360825 Text en Copyright © 2015 Eleonora Scaioli et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Scaioli, Eleonora Cardamone, Carla Liverani, Elisa Munarini, Alessandra Hull, Mark A. Belluzzi, Andrea The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid |
title | The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid |
title_full | The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid |
title_fullStr | The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid |
title_full_unstemmed | The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid |
title_short | The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid |
title_sort | pharmacokinetic profile of a new gastroresistant capsule preparation of eicosapentaenoic acid as the free fatty acid |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538368/ https://www.ncbi.nlm.nih.gov/pubmed/26339608 http://dx.doi.org/10.1155/2015/360825 |
work_keys_str_mv | AT scaiolieleonora thepharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT cardamonecarla thepharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT liveranielisa thepharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT munarinialessandra thepharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT hullmarka thepharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT belluzziandrea thepharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT scaiolieleonora pharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT cardamonecarla pharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT liveranielisa pharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT munarinialessandra pharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT hullmarka pharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid AT belluzziandrea pharmacokineticprofileofanewgastroresistantcapsulepreparationofeicosapentaenoicacidasthefreefattyacid |